Exemestane Completed Phase 2 Trials for Cancer, Breast / Estrogen Receptor-Positive Breast Cancer / ER+ Breast Cancer / Breast Cancer, Estrogen Receptor-Positive Treatment

clinicaltrials.gov IdentifierTitleDrugs
NCT00810797Exemestane in Treating Postmenopausal Women With Stage IV Breast Cancer
NCT00432172Selective Neoadjuvant Treatment According to Immunohistochemical Subtype for HER2 Negative Breast Cancer Patients
NCT01783444A Phase II Study of Everolimus in Combination With Exemestane Versus Everolimus Alone Versus Capecitabine in Advance Breast Cancer.
NCT00128843Exemestane Versus Anastrozole as First Line Hormone Therapy in Postmenopausal Metastatic Breast Cancer Patients
NCT00201864Exemestane in Combination With Fulvestrant in Postmenopausal Women With Hormone Sensitive Advanced Breast Cancer
NCT00941330Exemestane or Docetaxel-Cytoxan in Low Recurrence Score Cancers
NCT00010010Exemestane Plus Goserelin in Treating Premenopausal Women With Metastatic Breast Cancer
NCT01234857A Study of Ridaforolimus (MK-8669) in Combination With Dalotuzumab (MK-0646) Compared to Standard of Care Treatment in Estrogen Receptor Positive Breast Cancer Patients (MK-8669-041 AM3)
NCT02549430To Reverse ENDocrine Resistance Trial - PD 0332991 Monotherapy vs PD 0332991 in Combination With the Endocrine Therapy
NCT00676663Study to Evaluate Exemestane With and Without SNDX-275 in Treatment of Postmenopausal Women With Advanced Breast Cancer
NCT01004081Hormone Receptor Positive Metastatic Breast Cancer (HR+ mBC) BIIB021 Plus Aromasin Schedule Finding
NCT00767520Safety and Efficacy of Exemestane Plus Dasatinib Versus Placebo for Advanced ER+ Breast Cancer
NCT00201773Exemestane With Celecoxib as Neoadjuvant Treatment in Postmenopausal Women With Stage II, III, and IV Breast Cancer